✨ Free AI Report
Aditxt, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Aditxt, Inc.
Company Research

Aditxt, Inc.: Business Overview, Financials & Competitive Analysis

Aditxt, Inc. scores 3/10 on the AskCyborg Cyborg Score (Challenged). Early-stage biotech with promising immune-focused technology platforms facing severe capital constraints and stockholder dilution challenges. Aditxt stock last traded at $0.0637, down 16.32% from the previous close, and over the past 12 months has lost 100.0%, with a market capitalization of $60.4K classified as a micro-cap stock. The company faces.

What is Aditxt, Inc.'s industry? Aditxt, Inc. (aditxt.com) operates in Orphan Drugs. AskCyborg classifies Aditxt, Inc. under Orphan Drugs in its company registry.

Aditxt, Inc. is a commercial-stage company that discovers and develops products in immune health, precision health, population health, women's health, and neurologic health. The company operates as a Nasdaq-listed soc...

3/ 10Challenged

Cyborg Score thesis

Early-stage biotech with promising immune-focused technology platforms facing severe capital constraints and stockholder dilution...

Read the full analyst-debate transcript →
Industry Orphan Drugs
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Aditxt, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Aditxt, Inc.

AskCyborg analysts argue the bull and bear cases for Aditxt, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Aditxt, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Aditxt, Inc. Overview

Pro stress-test →

Aditxt, Inc. is a commercial-stage company that discovers and develops products in immune health, precision health, population health, women's health, and neurologic health. The company operates as a Nasdaq-listed social innovation platform focused on immune health, precision diagnostics and women's health through programs like Adimune and Pearsanta.

Strategic Profile

Pro stress-test →

The company develops AditxtScore that enables individuals to understand, manage, and monitor their immune profiles, and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that mimics the way the body naturally induces tolerance to its tissues. Pearsanta, Aditxt's majority owned precision diagnostics and personalized medicine subsidiary, was advancing toward commercial launch in the second half of 2025 with blood-based tests for Prostate Cancer and Endometriosis.

Competitive Landscape

Pro stress-test →

Aditxt operates under license agreements with Loma Linda University and Leland Stanford Junior University, leveraging academic partnerships for credibility. The company competes in the crowded immunology and precision diagnostics markets against larger biotech firms and specialized diagnostic companies, but maintains differentiation through its immune-mapping platform and multi-indication therapeutic pipeline.

Industry Context

Aditxt, Inc. operates in Orphan Drugs.

Key facts

Founded: 2017 · Headquarters: Mountain View, California · Revenue: $3K · Market cap: $60.4K

What the analysts stress-tested

The top findings that survived the multi-agent debate for Aditxt, Inc..

  • Aditxt regained compliance with Nasdaq's minimum bid price requirement in March 2026, addressing near-term delisting risk
  • Pearsanta has engaged Dominari Securities as lead underwriter for a planned IPO to support commercialization efforts, signaling potential capital raising through subsidiary spin-off
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • May 2026Shareholders approve reverse split and governance measures
  • April 2026Announces new note financing and debt obligations; major investor quietly boosts position
  • +1 moreTrack every material event for Aditxt, Inc. as it happens. Explore monitoring →
Get alerted when Aditxt, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

ApobiologicsImmune tolerance-based therapeutics→Guardant HealthPrecision diagnostics and blood-based cancer detection→Foundation MedicineGenomic tumor profiling for cancer diagnostics→

Compare Aditxt, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Aditxt, Inc. operates in Orphan Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Orphan Drugs research →
NEW · MCP server

Ask your AI assistant about Aditxt, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Aditxt, Inc. and its top competitor on Cyborg Score”
“What did Aditxt, Inc. do this quarter?”
“Is Aditxt, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Aditxt, Inc. do?+
Aditxt, Inc. is a commercial-stage company that discovers and develops products in immune health, precision health, population health, women's health, and neurologic health. The company operates as a Nasdaq-listed soc...
What is Aditxt, Inc.'s Cyborg Score?+
Aditxt, Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Aditxt, Inc.'s main competitors?+
Named competitors include Apobiologics, Guardant Health, Foundation Medicine. The full competitive landscape is in the AskCyborg report.
How can I get the full Aditxt, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Aditxt, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Aditxt, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.